Do analysts recommend CABR or SPRC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Caring Brands 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 SciSparc 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, CABR or SPRC?

Caring Brands has higher earnings, but lower revenue than SciSparc. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Caring Brands $2.75K 4,569.18 -$6.28M -$0.74 N/A SciSparc $860K 4.37 -$12.18M N/A N/A

Is CABR or SPRC more profitable?

SciSparc's return on equity of 0.00% beat Caring Brands' return on equity. Company Net Margins Return on Equity Return on Assets Caring Brands N/A -862.39% -302.23% SciSparc N/A N/A N/A

Do analysts recommend GRTX or SPRC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galera Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SciSparc 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, GRTX or SPRC?

SciSparc has higher revenue and earnings than Galera Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Galera Therapeutics N/A N/A -$59.08M $0.64 0.14 SciSparc $860K 4.37 -$12.18M N/A N/A

Is GRTX or SPRC more profitable?

Company Net Margins Return on Equity Return on Assets Galera Therapeutics N/A N/A -99.34% SciSparc N/A N/A N/A

Do analysts prefer SPRC or COCP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SciSparc 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cocrystal Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, SPRC or COCP?

Cocrystal Pharma has lower revenue, but higher earnings than SciSparc. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SciSparc $860K 4.37 -$12.18M N/A N/A Cocrystal Pharma $330K 46.79 -$8.83M -$0.76 N/A

Is SPRC or COCP more profitable?

SciSparc's return on equity of 0.00% beat Cocrystal Pharma's return on equity. Company Net Margins Return on Equity Return on Assets SciSparc N/A N/A N/A Cocrystal Pharma N/A -164.57% -108.08%

Do analysts recommend SPRC or ELOX?

Eloxx Pharmaceuticals has a consensus target price of $41.50, indicating a potential upside of 121.22%. Given Eloxx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Eloxx Pharmaceuticals is more favorable than SciSparc. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SciSparc 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Eloxx Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has stronger earnings & valuation, SPRC or ELOX?

Eloxx Pharmaceuticals has higher revenue and earnings than SciSparc. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SciSparc $860K 4.37 -$12.18M N/A N/A Eloxx Pharmaceuticals $6.36M 2.04 -$5.99M -$15.29 N/A

Is SPRC or ELOX more profitable?

Company Net Margins Return on Equity Return on Assets SciSparc N/A N/A N/A Eloxx Pharmaceuticals N/A N/A N/A

Does the media prefer SPRC or ELOX?

In the previous week, SciSparc had 3 more articles in the media than Eloxx Pharmaceuticals. MarketBeat recorded 7 mentions for SciSparc and 4 mentions for Eloxx Pharmaceuticals. SciSparc's average media sentiment score of 0.68 beat Eloxx Pharmaceuticals' score of 0.57 indicating that SciSparc is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SciSparc 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eloxx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer SPRC or CALC?

CalciMedica has a consensus price target of $10.00, suggesting a potential upside of 1,381.26%. Given CalciMedica's stronger consensus rating and higher possible upside, analysts plainly believe CalciMedica is more favorable than SciSparc. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SciSparc 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CalciMedica 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation and earnings, SPRC or CALC?

SciSparc has higher revenue and earnings than CalciMedica. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SciSparc $860K 4.37 -$12.18M N/A N/A CalciMedica N/A N/A -$29.56M -$1.36 N/A

Is SPRC or CALC more profitable?

SciSparc's return on equity of 0.00% beat CalciMedica's return on equity. Company Net Margins Return on Equity Return on Assets SciSparc N/A N/A N/A CalciMedica N/A -863.40% -155.24%

Does the media refer more to SPRC or CALC?

In the previous week, CalciMedica had 4 more articles in the media than SciSparc. MarketBeat recorded 11 mentions for CalciMedica and 7 mentions for SciSparc. SciSparc's average media sentiment score of 0.68 beat CalciMedica's score of 0.56 indicating that SciSparc is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SciSparc 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CalciMedica 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

SciSparc (SPRC) Competitors

$6.59 -0.10 (-1.49%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$6.60 +0.01 (+0.15%)

As of 08/14/2026 07:34 PM Eastern

Compare

SPRC vs. CABR, GRTX, COCP, ELOX, and CALC

Should you buy SciSparc stock or one of its competitors? SciSparc's main competitors and comparable companies include Caring Brands (CABR), Galera Therapeutics (GRTX), Cocrystal Pharma (COCP), Eloxx Pharmaceuticals (ELOX), and CalciMedica (CALC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does SciSparc compare to Caring Brands?

Caring Brands (NASDAQ:CABR) and SciSparc (NASDAQ:SPRC) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.

Caring Brands has higher earnings, but lower revenue than SciSparc.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caring Brands	$2.75K	4,569.18	-$6.28M	-$0.74	N/A
SciSparc	$860K	4.37	-$12.18M	N/A	N/A

25.1% of SciSparc shares are held by institutional investors. 14.6% of Caring Brands shares are held by company insiders. Comparatively, 1.5% of SciSparc shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, SciSparc had 4 more articles in the media than Caring Brands. MarketBeat recorded 7 mentions for SciSparc and 3 mentions for Caring Brands. Caring Brands' average media sentiment score of 1.53 beat SciSparc's score of 0.68 indicating that Caring Brands is being referred to more favorably in the media.

Company	Overall Sentiment
Caring Brands	Very Positive
SciSparc	Positive

SciSparc's return on equity of 0.00% beat Caring Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Caring Brands	N/A	-862.39%	-302.23%
SciSparc	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caring Brands	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
SciSparc	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

SciSparc beats Caring Brands on 5 of the 9 factors compared between the two stocks.

How does SciSparc compare to Galera Therapeutics?

Galera Therapeutics (NASDAQ:GRTX) and SciSparc (NASDAQ:SPRC) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership, media sentiment and dividends.

50.8% of Galera Therapeutics shares are held by institutional investors. Comparatively, 25.1% of SciSparc shares are held by institutional investors. 12.9% of Galera Therapeutics shares are held by insiders. Comparatively, 1.5% of SciSparc shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

SciSparc has higher revenue and earnings than Galera Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galera Therapeutics	N/A	N/A	-$59.08M	$0.64	0.14
SciSparc	$860K	4.37	-$12.18M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galera Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
SciSparc	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, SciSparc had 7 more articles in the media than Galera Therapeutics. MarketBeat recorded 7 mentions for SciSparc and 0 mentions for Galera Therapeutics. SciSparc's average media sentiment score of 0.68 beat Galera Therapeutics' score of 0.00 indicating that SciSparc is being referred to more favorably in the news media.

Company	Overall Sentiment
Galera Therapeutics	Neutral
SciSparc	Positive

Galera Therapeutics has a beta of 2.6, indicating that its share price is 160% more volatile than the broader market. Comparatively, SciSparc has a beta of 2.78, indicating that its share price is 178% more volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Galera Therapeutics	N/A	N/A	-99.34%
SciSparc	N/A	N/A	N/A

Summary

SciSparc beats Galera Therapeutics on 7 of the 9 factors compared between the two stocks.

How does SciSparc compare to Cocrystal Pharma?

SciSparc (NASDAQ:SPRC) and Cocrystal Pharma (NASDAQ:COCP) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

SciSparc has a beta of 2.78, suggesting that its share price is 178% more volatile than the broader market. Comparatively, Cocrystal Pharma has a beta of 1.43, suggesting that its share price is 43% more volatile than the broader market.

SciSparc's return on equity of 0.00% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SciSparc	N/A	N/A	N/A
Cocrystal Pharma	N/A	-164.57%	-108.08%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SciSparc	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cocrystal Pharma has lower revenue, but higher earnings than SciSparc.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SciSparc	$860K	4.37	-$12.18M	N/A	N/A
Cocrystal Pharma	$330K	46.79	-$8.83M	-$0.76	N/A

25.1% of SciSparc shares are held by institutional investors. Comparatively, 6.7% of Cocrystal Pharma shares are held by institutional investors. 1.5% of SciSparc shares are held by company insiders. Comparatively, 39.4% of Cocrystal Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, SciSparc had 5 more articles in the media than Cocrystal Pharma. MarketBeat recorded 7 mentions for SciSparc and 2 mentions for Cocrystal Pharma. SciSparc's average media sentiment score of 0.68 beat Cocrystal Pharma's score of -0.56 indicating that SciSparc is being referred to more favorably in the media.

Company	Overall Sentiment
SciSparc	Positive
Cocrystal Pharma	Negative

Summary

SciSparc beats Cocrystal Pharma on 7 of the 10 factors compared between the two stocks.

How does SciSparc compare to Eloxx Pharmaceuticals?

SciSparc (NASDAQ:SPRC) and Eloxx Pharmaceuticals (NASDAQ:ELOX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.

Eloxx Pharmaceuticals has higher revenue and earnings than SciSparc.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SciSparc	$860K	4.37	-$12.18M	N/A	N/A
Eloxx Pharmaceuticals	$6.36M	2.04	-$5.99M	-$15.29	N/A

In the previous week, SciSparc had 3 more articles in the media than Eloxx Pharmaceuticals. MarketBeat recorded 7 mentions for SciSparc and 4 mentions for Eloxx Pharmaceuticals. SciSparc's average media sentiment score of 0.68 beat Eloxx Pharmaceuticals' score of 0.57 indicating that SciSparc is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SciSparc	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eloxx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Net Margins	Return on Equity	Return on Assets
SciSparc	N/A	N/A	N/A
Eloxx Pharmaceuticals	N/A	N/A	N/A

SciSparc has a beta of 2.78, indicating that its share price is 178% more volatile than the broader market. Comparatively, Eloxx Pharmaceuticals has a beta of -1864.08, indicating that its share price is 186,508% less volatile than the broader market.

Eloxx Pharmaceuticals has a consensus target price of $41.50, indicating a potential upside of 121.22%. Given Eloxx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Eloxx Pharmaceuticals is more favorable than SciSparc.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SciSparc	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Eloxx Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

25.1% of SciSparc shares are owned by institutional investors. Comparatively, 2.9% of Eloxx Pharmaceuticals shares are owned by institutional investors. 1.5% of SciSparc shares are owned by company insiders. Comparatively, 25.9% of Eloxx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Eloxx Pharmaceuticals beats SciSparc on 6 of the 11 factors compared between the two stocks.

How does SciSparc compare to CalciMedica?

SciSparc (NASDAQ:SPRC) and CalciMedica (NASDAQ:CALC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

CalciMedica has a consensus price target of $10.00, suggesting a potential upside of 1,381.26%. Given CalciMedica's stronger consensus rating and higher possible upside, analysts plainly believe CalciMedica is more favorable than SciSparc.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SciSparc	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CalciMedica	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

SciSparc has a beta of 2.78, suggesting that its stock price is 178% more volatile than the broader market. Comparatively, CalciMedica has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market.

SciSparc has higher revenue and earnings than CalciMedica.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SciSparc	$860K	4.37	-$12.18M	N/A	N/A
CalciMedica	N/A	N/A	-$29.56M	-$1.36	N/A

25.1% of SciSparc shares are held by institutional investors. 1.5% of SciSparc shares are held by company insiders. Comparatively, 28.3% of CalciMedica shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, CalciMedica had 4 more articles in the media than SciSparc. MarketBeat recorded 11 mentions for CalciMedica and 7 mentions for SciSparc. SciSparc's average media sentiment score of 0.68 beat CalciMedica's score of 0.56 indicating that SciSparc is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SciSparc	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CalciMedica	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

SciSparc's return on equity of 0.00% beat CalciMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SciSparc	N/A	N/A	N/A
CalciMedica	N/A	-863.40%	-155.24%

Summary

SciSparc beats CalciMedica on 7 of the 12 factors compared between the two stocks.

Get SciSparc News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPRC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SPRC vs. The Competition

Export

Metric	SciSparc	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.78M	$11.90B	$7.02B	$13.07B
Dividend Yield	N/A	2.70%	2.57%	10.45%
P/E Ratio	N/A	777.57	270.72	25.33
Price / Sales	4.37	753.89	574.35	73.89
Price / Cash	N/A	66.45	70.48	50.90
Price / Book	0.51	11.60	12.92	6.25
Net Income	-$12.18M	$2.77B	$3.45B	$347.82M
7 Day Performance	-4.91%	0.14%	1.15%	1.08%
1 Month Performance	34.49%	0.06%	1.37%	0.82%
1 Year Performance	-83.76%	145.15%	62.52%	20.99%

SciSparc Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SPRC SciSparc	0.5735 of 5 stars	$6.59 -1.5%	N/A	-85.1%	$3.78M	$860K	N/A	4	Short Interest Increase
CABR Caring Brands	0.916 of 5 stars	$1.56 flat	N/A	N/A	$14.18M	N/A	N/A	4	Positive News Earnings Report Short Interest Decrease
GRTX Galera Therapeutics	N/A	$0.09 flat	N/A	+300.0%	$14.12M	N/A	N/A	30
COCP Cocrystal Pharma	0.9252 of 5 stars	$1.02 +4.1%	N/A	-33.3%	$13.51M	N/A	N/A	10	Positive News Earnings Report
ELOX Eloxx Pharmaceuticals	2.8742 of 5 stars	$17.53 -4.9%	$41.50 +136.7%	N/A	$12.69M	$6.36M	N/A	N/A	Earnings Report Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SPRC) was last updated on 8/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SciSparc (SPRC) Competitors

SPRC vs. CABR, GRTX, COCP, ELOX, and CALC

How does SciSparc compare to Caring Brands?

Summary

How does SciSparc compare to Galera Therapeutics?

Summary

How does SciSparc compare to Cocrystal Pharma?

Summary

How does SciSparc compare to Eloxx Pharmaceuticals?

Summary

How does SciSparc compare to CalciMedica?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRC vs. The Competition

SciSparc Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

SciSparc (SPRC) Competitors

SPRC vs. CABR, GRTX, COCP, ELOX, and CALC

How does SciSparc compare to Caring Brands?

Which has preferable valuation and earnings, CABR or SPRC?

Do institutionals and insiders have more ownership in CABR or SPRC?

Does the media refer more to CABR or SPRC?

Is CABR or SPRC more profitable?

Do analysts recommend CABR or SPRC?

Summary

How does SciSparc compare to Galera Therapeutics?

Do insiders & institutionals have more ownership in GRTX or SPRC?

Which has better valuation & earnings, GRTX or SPRC?

Do analysts recommend GRTX or SPRC?

Does the media favor GRTX or SPRC?

Which has more risk and volatility, GRTX or SPRC?

Is GRTX or SPRC more profitable?

Summary

How does SciSparc compare to Cocrystal Pharma?

Which has more risk & volatility, SPRC or COCP?

Is SPRC or COCP more profitable?

Do analysts prefer SPRC or COCP?

Which has higher earnings & valuation, SPRC or COCP?

Do institutionals & insiders hold more shares of SPRC or COCP?

Does the media refer more to SPRC or COCP?

Summary

How does SciSparc compare to Eloxx Pharmaceuticals?

Which has stronger earnings & valuation, SPRC or ELOX?

Does the media prefer SPRC or ELOX?

Is SPRC or ELOX more profitable?

Which has more volatility and risk, SPRC or ELOX?

Do analysts recommend SPRC or ELOX?

Do institutionals and insiders believe in SPRC or ELOX?

Summary

How does SciSparc compare to CalciMedica?

Do analysts prefer SPRC or CALC?

Which has more volatility and risk, SPRC or CALC?

Which has stronger valuation and earnings, SPRC or CALC?

Do insiders and institutionals believe in SPRC or CALC?

Does the media refer more to SPRC or CALC?

Is SPRC or CALC more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRC vs. The Competition

SciSparc Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools